Sanofi has reiterated its interest in the acquisition of Medivation and the French pharma's CEO has toughened up his language. Meanwhile, despite lots of speculation about other potential suitors, none has yet to come forward publicly.
Following "extensive conversations" with Medivation Inc.'s "top shareholders," Sanofi's CEO Olivier Brandicourt believes there is "overwhelming support" for the transaction.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
